Announcements Trials

Browse Landscape

Phase

Phase 2 10 Phase 3 3 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Capecitabine 17 Paclitaxel 16 Docetaxel 13 Carboplatin 12 Cyclophosphamide 11 Gemcitabine 9 Epirubicin 9 Trastuzumab 8 Letrozole 8 Doxorubicin 7 pertuzumab 5 Cisplatin 5 Vinorelbine 4 130-nm albumin-bound paclitaxel 4 exemestane 3 Zoledronic Acid 3 Tamoxifen 3 Neoadjuvant Therapy 3 Lapatinib 3 Injections 3 Drug Therapy 3 Ado-Trastuzumab Emtansine 3 AC protocol 3 pyrotinib 2 palbociclib 2 camrelizumab 2 apatinib 2 Thiotepa 2 Taxes 2 Standard of Care 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × inavolisib × Breast × Clear all

NCT04191499 2026-03-17

INAVO120

Hoffmann-La Roche

Phase 2/3 Active not recruiting

325 enrolled 14 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡